According to Mordor Intelligence, the ventricular assist devices market size is valued at USD 1.88 billion in 2026, rising ...

Enrolment for the US-based trial is scheduled to start in mid-2026, with initial results expected in the fourth quarter.

NEW ORLEANS, Nov. 9 - A heart ventricular assist device (VAD) is used as a bridge to organ transplantation, maintaining a patient's cardiac function until a donor organ becomes available. In some ...

Nat Clin Pract Cardiovasc Med. 2006;3(7):377-386. Special silicone cannulae connect the blood pumps to the body (Figure 2). These cannulae are anastomosed to the right atrium and pulmonary artery for ...

BrioHealth has received conditional FDA approval to conduct a clinical evaluation of its ventricular assist device in ...

The characteristics described in this table are general. The intra-aortic balloon pump has been excluded since to it does not generate its own volume stroke. *Clinical approval of ECMO is variable ...

This analysis evaluates the relationship between hospital care delivery network fragmentation and in-hospital and 90-day outcomes. These networks may be novel targets for improving outcomes.

Patients with cardiogenic shock treated at hospitals with a higher volume of percutaneous microaxial VAD implantation in the US have lower mortality risk. Higher hospital procedure volume of ...

Medicare beneficiaries with heart failure who are Black or female were less likely to receive a left ventricular assist device (LVAD) implantation compared with White and male beneficiaries. Between ...

According to Mordor Intelligence, the ventricular assist devices market size is valued at USD 1.88 billion in 2026, rising from USD 1.73 billion ...